Latest 2024 PCa-related GuCS Meeting Coverage from MedPage Today:
More Evidence That ARSIs for Prostate Cancer Differ in Cognitive Effects -More fatigue, depression, worse reaction time with enzalutamide as compared with abiraterone, January 29, 2024:
medpagetoday.com/meetingcov...
Another Prostate Cancer Screening Candidate Outperforms Standard PSA Testing: Multiparametric Stockholm3 avoided far more unnecessary biopsies without sacrificing sensitivity, January 28, 2024:
medpagetoday.com/meetingcov...
Cabozantinib Plus Atezolizumab Delays Progression in mCRPC - Combination improved PFS versus more hormonal therapy, but control arm questioned, January 26, 2024:
medpagetoday.com/meetingcov...
Olaparib-Abiraterone in Biomarker-Selected mCRPC Tops Each Agent Alone - In small first-line trial, PFS more than doubled with combination, January 26, 2024:
medpagetoday.com/meetingcov...
Study Supports High-Dose RT, Long-Term ADT as Standard for High-Risk Prostate Cancer - OS, PFS, cancer-specific survival all improved, with no increase in toxicity, January 26, 2024:
medpagetoday.com/meetingcov...
Pick your poison and Stay S&W, ciao - cujoe